News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
268,199 Results
Type
Article (14263)
Company Profile (281)
Press Release (253655)
Multimedia
Podcasts (48)
Webinars (7)
Section
Business (79557)
Career Advice (153)
Deals (13234)
Drug Delivery (35)
Drug Development (50484)
Employer Resources (31)
FDA (5726)
Job Trends (5135)
News (144490)
Policy (10034)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (4)
2024 Biotech Bay Standard (10)
2024 Biotech Beach Digital (5)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (7)
2024 Genetown Standard (6)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (3)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (3)
2026 BioMidwest Elite (1)
2026 Bio NC Standard (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Genetown Standard (1)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (1)
Academia (916)
Accelerated approval (2)
Adcomms (12)
Allergies (51)
Alliances (21682)
ALS (64)
Alzheimer's disease (849)
Antibody-drug conjugate (ADC) (100)
Approvals (5754)
Artificial intelligence (123)
Autoimmune disease (18)
Automation (5)
Bankruptcy (105)
Best Places to Work (4559)
BIOSECURE Act (6)
Biosimilars (43)
Biotechnology (232)
Bladder cancer (58)
Brain cancer (20)
Breast cancer (155)
Cancer (1476)
Cardiovascular disease (116)
Career advice (133)
Career pathing (2)
CAR-T (116)
Cell therapy (328)
Cervical cancer (8)
Clinical research (41089)
Collaboration (541)
Compensation (258)
Complete response letters (13)
COVID-19 (1037)
CRISPR (41)
C-suite (163)
Cystic fibrosis (76)
Data (1515)
Denatured (11)
Depression (29)
Diabetes (137)
Diagnostics (1299)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (85)
Drug pricing (28)
Drug shortages (3)
Duchenne muscular dystrophy (90)
Earnings (29826)
Editorial (18)
Employer branding (4)
Employer resources (29)
Events (48618)
Executive appointments (459)
FDA (6422)
Featured Employer (30)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (499)
Gene editing (96)
Generative AI (10)
Gene therapy (252)
GLP-1 (365)
Government (1079)
Grass and pollen (2)
Guidances (21)
Healthcare (6596)
Huntington's disease (22)
IgA nephropathy (25)
Immunology and inflammation (91)
Indications (20)
Infectious disease (1102)
Inflammatory bowel disease (114)
Inflation Reduction Act (8)
Influenza (19)
Intellectual property (67)
Interviews (17)
IPO (7276)
IRA (11)
Job creations (862)
Job search strategy (127)
Kidney cancer (7)
Labor market (5)
Layoffs (208)
Leadership (3)
Legal (1386)
Liver cancer (33)
Lung cancer (205)
Lymphoma (100)
Machine learning (3)
Management (7)
Manufacturing (138)
MASH (53)
Medical device (2599)
Medtech (2600)
Mergers & acquisitions (6289)
Metabolic disorders (388)
Multiple sclerosis (53)
NASH (13)
Neurodegenerative disease (68)
Neuropsychiatric disorders (25)
Neuroscience (1256)
NextGen: Class of 2025 (2017)
Non-profit (852)
Northern California (1696)
Now hiring (22)
Obesity (193)
Opinion (102)
Ovarian cancer (63)
Pain (43)
Pancreatic cancer (56)
Parkinson's disease (121)
Partnered (8)
Patents (128)
Patient recruitment (76)
Peanut (35)
People (25648)
Pharmaceutical (47)
Pharmacy benefit managers (5)
Phase I (14509)
Phase II (19114)
Phase III (12083)
Pipeline (804)
Policy (44)
Postmarket research (852)
Preclinical (6140)
Press Release (30)
Prostate cancer (62)
Psychedelics (35)
Radiopharmaceuticals (213)
Rare diseases (292)
Real estate (1419)
Recruiting (12)
Regulatory (8637)
Reports (15)
Research institute (940)
Resumes & cover letters (17)
Rett syndrome (4)
RNA editing (5)
RSV (10)
Schizophrenia (59)
Series A (98)
Series B (63)
Service/supplier (1)
Sickle cell disease (40)
Southern California (1485)
Special edition (11)
Spinal muscular atrophy (117)
Sponsored (12)
Startups (1974)
State (1)
Stomach cancer (4)
Supply chain (23)
Tariffs (8)
The Weekly (36)
United States (13211)
Vaccines (214)
Venture capitalists (32)
Weight loss (109)
Women's health (15)
Worklife (2)
Date
Today (120)
Last 7 days (504)
Last 30 days (1573)
Last 365 days (19589)
2025 (6200)
2024 (20556)
2023 (22435)
2022 (26835)
2021 (27810)
2020 (23366)
2019 (16225)
2018 (11743)
2017 (13747)
2016 (11840)
2015 (14369)
2014 (10404)
2013 (7506)
2012 (7558)
2011 (7636)
2010 (7434)
Location
Africa (148)
Alabama (42)
Alaska (2)
Arizona (53)
Arkansas (5)
Asia (17311)
Australia (2935)
California (3843)
Canada (1140)
China (358)
Colorado (149)
Connecticut (151)
Delaware (102)
Europe (37250)
Florida (463)
Georgia (115)
Idaho (16)
Illinois (231)
India (10)
Indiana (91)
Iowa (2)
Japan (73)
Kansas (62)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (472)
Massachusetts (3074)
Michigan (70)
Minnesota (144)
Mississippi (1)
Missouri (24)
Montana (14)
Nebraska (4)
Nevada (17)
New Hampshire (14)
New Jersey (959)
New Mexico (12)
New York (1039)
North Carolina (550)
North Dakota (5)
Northern California (1696)
Ohio (112)
Oklahoma (9)
Oregon (21)
Pennsylvania (737)
Puerto Rico (6)
Rhode Island (19)
South America (208)
South Carolina (4)
Southern California (1485)
Tennessee (25)
Texas (446)
Utah (53)
Virginia (78)
Washington D.C. (30)
Washington State (351)
Wisconsin (15)
268,199 Results for "galectin therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update
April 1, 2025
·
9 min read
Press Releases
Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2025 Congress
April 15, 2025
·
5 min read
MASH
Phase III MASH Miss Sends Galectin Stock Tumbling
Galectin’s shares tanked in premarket trading Friday after the biotech revealed its lead asset missed the primary endpoint for its Phase IIb/III trial for patients with a type of liver cirrhosis.
December 20, 2024
·
1 min read
·
Kate Goodwin
Press Releases
Galectin Therapeutics to Present at the 2025 MASH-TAG Conference
January 10, 2025
·
2 min read
Press Releases
Galectin Therapeutics Reports Significant Reduction in New Varices with Belapectin in U.S. Patient Population from the NAVIGATE Trial
February 19, 2025
·
6 min read
Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Conference
Galectin Therapeutics Inc. announced today the Company will be attending and presenting at the H.C. Wainwright 2 nd Annual BioConnect Investor Conference.
May 13, 2024
·
2 min read
Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 Congress
Galectin Therapeutics Inc. today announced that it will attend the EASL 2024 meeting and deliver a scientific presentation. The meeting will be held June 5-8, 2024, in Milan, Italy.
June 4, 2024
·
5 min read
Press Releases
Bioxytran Signs NDA with the University of Georgia to Evaluate Galectin Antagonists for Bird Flu Treatment in Chickens
March 19, 2025
·
2 min read
Business
Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update
Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2023.
March 29, 2024
·
9 min read
Business
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update
Galectin Therapeutics, Inc. today reported financial results and provided a business update for the quarter ended March 31, 2024.
May 15, 2024
·
8 min read
1 of 26,820
Next
